BAX Stock Recent News

Novo Nordisk (NVO) was named Yahoo Finance's Company of the Year thanks to the success of its diabetes and weight loss drugs, Ozempic and Wegovy. But there are other ways you can play the GLP-1 hype.

Baxter International stock rated Buy, agreeing with Wall Street consensus. Tailwinds coming from positive revenue, earnings, and equity growth. Cheap share price below moving average combined with +3% dividend yield, for a company that returned to profitability.

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter International on Thursday beat Wall Street expectations for third-quarter revenue and profit, as a recovery in surgical procedure volumes after the pandemic helped drive the demand for its medical devices higher.

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or Stryker (SYK). But which of these two stocks is more attractive to value investors?

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.

A drug made by a rival tested well in a clinical trial for kidney disease. That treatment is currently a very hot product, but for different indications.

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.